

Ref: FOI/GS/ID 8073

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

27 March 2023

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Oesophageal and Gastric cancer.

*You asked:*

*Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:*

- a. CAPOX (Capecitabine with Oxaliplatin)*
- b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)*
- c. Lonsurf (Trifluridine - tipiracil)*
- d. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*
- e. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*
- f. Any other systemic anti-cancer therapy*
- g. Palliative care only*

*Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:*

- a. Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)*
- b. Nivolumab monotherapy*
- c. Nivolumab and Ipilimumab*
- d. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*
- e. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*
- f. Any other systemic anti-cancer therapy*
- g. Palliative care only*

*Q3. Does your trust participate in any clinical trials for gastric cancer? If so, please provide the name of each trial and the number of patients taking part.*

*Q4. Does your trust participate in any clinical trials for oesophageal cancer? If so, please provide the name of each trial and the number of patients taking part.*

Trust response:

Q1.

a.	3
b.	2
c.	0
d.	0
e.	0
f.	19
g.	3

Q2.

a.	42
b.	2
c.	0
d.	1
e.	1
f.	17
g.	5

Q3 & Q4

IRAS	Short Title	Full Title	Site Status	No. Patients Recruited
120104	Add-Aspirin	A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.	Closed to recruitment - in follow up	72
169633	SCOPE 2	A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemoradiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET)	Open	9
154429	PLATFORM	Planning treatment for oesophago-gastric cancer: a randomised maintenance therapy trial (PLATFORM Trial)	Open	10